Free Trial
NASDAQ:KYMR

Kymera Therapeutics Q3 2025 Earnings Report

Kymera Therapeutics logo
$57.90 +1.90 (+3.39%)
Closing price 04:00 PM Eastern
Extended Trading
$57.89 -0.01 (-0.02%)
As of 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kymera Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.73
Beat/Miss
N/A
One Year Ago EPS
N/A

Kymera Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kymera Therapeutics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, October 30, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Kymera Therapeutics Earnings Headlines

Kymera Therapeutics (NASDAQ:KYMR) Sets New 52-Week High on Analyst Upgrade
Alert: Prepare for Trump's Dollar Overhaul
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."tc pixel
See More Kymera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kymera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kymera Therapeutics and other key companies, straight to your email.

About Kymera Therapeutics

Kymera Therapeutics (NASDAQ:KYMR) is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology. Its lead program, a degrader targeting interleukin‐1 receptor–associated kinase 4 (IRAK4), is being evaluated for inflammatory and autoimmune diseases. In parallel, Kymera is advancing degraders against transcription factors and other intracellular targets implicated in hematologic malignancies. Preclinical efforts also include collaborations with global pharmaceutical partners to expand the application of its protein‐degradation technology to additional disease routes.

Kymera operates research and development facilities in Massachusetts and maintains collaborations with academic institutions and biotech partners in North America and Europe. The company’s multi‐disciplinary team brings together expertise in structural biology, chemistry, pharmacology and clinical development. Since becoming a publicly traded company on the Nasdaq exchange under the ticker symbol KYMR, Kymera has continued to build its leadership bench to support late‐stage trials, regulatory interactions and future commercialization efforts.

Rick Wagner serves as President and Chief Executive Officer, leading Kymera through its transition from a discovery‐focused entity to a clinical‐stage organization. Under his guidance, the company has expanded its internal capabilities and entered strategic research partnerships to accelerate the development of protein degraders. As Kymera progresses key programs into later‐stage clinical studies, it aims to validate targeted protein degradation as a new therapeutic modality that can address diseases with limited treatment options.

View Kymera Therapeutics Profile

More Earnings Resources from MarketBeat